How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types
We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat
A look at progress and new developments in cancer biomarker developments
Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer
In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.
George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing…
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
There's a wealth of clinical and biomarker data to explore in RCC, which may have implications for prescribing changes in the near future
Highlights from several solid tumour trials in both early and late stage disease.
Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.
Highlights from various breast cancer trials and new pipeline developments
Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.
From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years
10 developmental therapeutics abstracts to watch out for at the ASCO 2020 virtual meeting
There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
Does modality matter in oncology drug development and if so, where?
Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)
What do we learn from the initial data with novel PROTAC technology?
A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.
A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview